Kennedy's Medical Momentum
10/17/2003 12:00 am EST
According to The Hulbert Financial Digest, Kevin Kennedy’s portfolios have risen on average an annual 43.8% rate since the end of 1998. In line with his newsletter's name–Coolcat Explosive Small Cap Growth Stock Report–his focus is on small, lesser-known issues showing very strong momentum. For those willing to assume the risks, here are his latest top picks.
"Our latest low-price momentum pick–which is a stock with a relative strength ranking of 99 out of 100– BioCryst Pharmaceuticals (BCRX NASDAQ). The stock is up from a low of just $0.82 a share. BioCryst designs and develops novel small-molecule drugs that block key enzymes essential for cancer, cardiovascular, autoimmune diseases, and viral infections. Enrollment in four Phase I trials for BioCryst's lead product candidate, BCX-1777, is underway at 11 cancer centers for patients with T-cell malignancies, hematologic malignancies, and other refractory cancers. BioCryst has several new enzyme targets in drug discovery including tissue factor/factor VII and hepatitis C polymerase.
"Our latest super-seven stock, which meets seven strict criteria for momentum, price, volume, and technical strength is Nyer Medical Group (NYER NASDAQ). Nyer is a holding company with operations in the medical products distribution and services business, retail pharmacy business, and emergency equipment and supplies. The company distributes more then 17,000 different medical equipment and supply products to hospitals, physicians, and nursing homes using relationship-based telemarketing, direct sales personnel, catalogs, and the Internet. These orders are filled by the company's distribution centers located in New England, South Florida, and Nevada."